Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSCIB1+ with Ipilimumab and Nivolumab in Advanced Melanoma
NCT07815574Phase 3Not yet recruiting
- Sponsor
- Scancell
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 2
01
Overview
A Phase 3 trial of iSCIB1+ in melanoma, sponsored by Scancell. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
iSCIB1+
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07815574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815574.